NIH Principles of Clinical Pharmacology Syllabus 2024-2025

Module 1: Introduction to Clinical Pharmacology		
Lectures	Post-Lecture Activities	
Introduction to Module 1 - Dr. Craig Thomas		
Introduction to Clinical Pharmacology and Therapeutics - Dr. Juan J.L. Lertora	Case Study: Steady-State Calculation	
Introduction to Pharmacology, Drug Development and Clinical Pharmacology -	Understanding the Basics of Pharmacology	
Dr. William D. Figg		
Practical Pharmacology - Dr. Anne Zajicek	Case Study: Practice with Prescriptions	
Biochemical Mechanisms for Drug Toxicity - Dr. A. Beasley Green	Case Study: Statins & Hepatotoxicity	
Ethics in Pediatric Clinical Pharmacology - Dr. Donna L. Snyder	Case Study: Pediatric Extrapolation	
Ethics in Adult Clinical Pharmacology - Dr. Ezekiel J. Emanuel	Principles of Ethics	
Module 2: Pharmacokineti	rs .	
Lectures	Post-Lecture Activities	
Introduction to Module 2 - Dr. Anne Zajicek		
Drug Absorption and Bio-availability - Dr. Jan Beumer	Case Study: The Impact of Food on	
brug Absolption and bio availability Dr. san beamer	Bioavailability	
Compartmental Analysis of Drug Distribution - Dr. Arthur Atkinson	Case Study: Effect of Protein Binding on V _d	
Noncompartmental vs. Compartmental Approaches to Pharmacokinetic	Case Study: Nonlinear PK Calculation	
Analysis - Dr. Paolo Vicini		
Population Pharmacokinetics - Dr. Robert R. Bies	Population Pharmacokinetic Modeling	
	Vignette by Dr. Robert R. Bies plus a	
	Population Pharmacokinetic Terminology	
	Activity	
Chemical Analysis of Drugs and Metabolites - Dr. Andrew Goey	Case Study by Dr. Robert Parise: Introduction	
Pharmacokinetics & Pharmacodynamics of Therapeutic Proteins – Dr. Bernd	to Mass Spectrometry Pharmacologic Characteristics of Therapeutic	
Meibohm	Proteins	
Module 3: Drug Metabolism and T	-	
Lectures	Post-Lecture Activities	
Introduction to Module 3 - Dr. Lisa M. Cordes		
Pathways of Drug Metabolism	Case Study by Dr. Lionel D. Lewis: "Victims &	
Part 1: Phase I Drug Metabolism - Dr. Kenneth Thummel	Perpetrators" in Therapeutics	
Part 2: Phase II Drug Metabolism - Dr. Deanna Kroetz		
P-Glycoprotein and Drug Transport	Case Study by Dr. Jomy M. George:	
Part 1: ABC Transporters in Health and Disease - Dr. Michael Gottesman	Transporter Mediated Drug-Drug Interactions	
Part 2: ABC Transporters in the Blood-Brain Barrier - Dr. Matthew Hall		
Membrane Transport - Dr. Kathy Giacomini	Membrane Transporters in Drug	
	Development	
Drug Transport Across the Blood Brain Barrier - Dr. Sadhana Jackson	Permeability of the Blood Brain Barrier	
Module 4: Pharmacokinetics and Drug Therapy	in Special Populations	
Lectures	Post-Lecture Activities	
Introduction to Module 4 - Dr. Bruce Waldrop		
Pharmacokinetic Considerations in Patients with Renal Impairment - Dr.	Case Study: Drug Dosing in Patients with	
Darren Roberts	Chronic Kidney Disease	
Pharmacokinetics in Patients Requiring Renal Replacement Therapy	Continuous Renal Replacement Therapy:	
Part 1: PK in Patients Requiring Hemodialysis - Dr. Arthur Atkinson	Who, When, Why, How	
Part 2: Continuous Renal Replacement Therapy - Dr. Gregory Susla		

Case Study: Dose Adjustments Based on

Child-Pugh Score

The Liver and Drugs - Dr. Jürgen Venitz

Drug Therapy in Pregnant and Nursing Women - Dr. Anne Zajicek	Case Study: Risks of Levetiracetam During Lactation
Developmental and Pediatric Pharmacology - Dr. John N. van den Anker	Developmental Changes That Influence Drug Disposition
Drug Therapy in the Geriatric Population - Dr. Darrell R. Abernethy	Case Study: DOACs in the Elderly
Pharmacokinetics and Obesity - Dr. Manjunath Pai	Case Study: Drug Dosing in Obesity
Module 5: Assessment of Drug	Effects
Lectures	Post-Lecture Activities
Introduction to Module 5 - Dr. Terry Seaton	-
Biomarkers of Drug Effects - Dr. Robert Schuck	Pharmacodynamic/Response Biomarkers
Pharmacodynamic and Pharmacokinetic Modeling of Data - Dr. Joga Gobburu	PK/PD Modeling Exercise by Dr. Cody J. Peer
Disease Progression Models - Dr. Diane Mould	Role of Disease Progression Models in Drug Development
Role of Pharmacodynamics in Drug Development - Dr. James Doroshow	Pharmacodynamic & Proof of Mechanism Biomarkers
Module 6: Drug Discovery and Dev	elopment
Lectures	Post-Lecture Activities
Introduction to Module 6 - Dr. William Zamboni	
Drug Discovery - Dr. Edward Sausville	Drug Discovery Basics
Quantitative Systems Pharmacology - Dr. D. Lansing Taylor	Integrating Diverse Data Sources into Computation Models
Combinatorial Drug Screening - Dr. Craig Thomas	Case Study: BRAF & MEK Inhibitors in Melanoma
Natural Products - Dr. Barry O'Keefe	Decisions on Screening Natural Products
Drug Formulation & Delivery - Dr. Robert Ternik	Biopharmaceutics Classification System
Considerations in the Development of Biologics - Dr. Mansoor Khan	Biosimilars
Drug Development in the Pediatric Population - Dr. Anne Zajicek	Clinical Research Involving Children
Animal Scale Up and First-in-Human Studies - Dr. Jerry Collins	Estimating the Starting Dose in FiH Studies
Dose Selection and Optimization in the Adult Population - Dr. Yaning Wang	Case Study: Secukinumab Dosing Optimization
Design of Clinical Drug Development Programs - Dr. Christopher D. Breder	Clinical Drug Development Path
FDA Approval Considerations - Dr. Paul Kluetz	Discussion on Clinical Trial Endpoints by Dr. Barry Goldspiel
Module 7: Pharmacogenomics and Pha	rmacotherapy
Lectures	Post-Lecture Activities

Introduction to Module 7 - Dr. Elvin Price	
Pharmacometabolomics: Implications for Clinical Pharmacology - Dr. Richard	Case Study: SSRIs & Pharmacometabolomics
Weinshilboum	
Overview of Pharmacogenomics - Dr. Howard McLeod	Case Study: Dosing Guidelines for
	Azathioprine & TPMT
Implementing Pharmacogenomics into Practice - Dr. Mary Relling	Drugs & Genes
Pharmacogenomics: FDA Perspective - Dr. Michael Pacanowski	Case Study: Ivacaftor & CFTR
Clinical Drug Interactions - Dr. Sarah Robertson	Case Study: Clinical Implications of Grapefruit
	Juice
Clinical Assessment of Adverse Drug Reactions - Dr. Christopher D. Breder	Case Study: Describing Adverse Events Using
	CTCAE
Post-Marketing Drug Safety Surveillance - Dr. Peter Waldron	Case Study: MedWatch Voluntary Reporting
Quality Assurance for Drug Therapy - Dr. Charles Daniels	Medication Use Evaluation

Topics of Special Interest (Supplementary Materials)

About This Module:

This Module contains supplementary materials for participants who are interested in learning more. Although these lectures are not classified as core lectures and are not part of the final exam, they will add to the participant's knowledge base on pharmacology.

Supplementary Lectures	Post-Lecture Activities
Use of Positron Emission Tomography (PET) in Pharmacokinetics - Dr. Robert	Basics of PET in PK
Innis	
Drug Transporters in ADME and Drug Action - Dr. Joseph Ware	Case Study: The Mystery of Loperamide
Enabling Technologies in Drug Formulation - Dr. Ping Gao	Understanding Drug Formulations
Computational Methods of Drug Discovery and Design - Dr. Glen Kellogg	Computational Methods Key Definitions
Immunotherapeutics - Dr. James Gulley	Case Study by Dr. Lisa M. Cordes:
	Immunotherapy-Related Adverse Events
T-Cell Therapies: Principles and Practice - Dr. James Yang	Structures of Adoptive Cell Therapies
NCI Drug Development Workshop: How to Advance a Therapeutic Candidate	Case Studies:
from Bench to Bedside	Development of Small Molecule Products
	Development of Biological Products